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*e capability of flavonoids in sensitizing cancer cells was demonstrated in numerous works to chemotherapy and converse
multidrug resistance by modulating efflux pumps and apoptosis mechanisms. *ree flavonoids, namely, bavachinin, tephrosin,
and candidone, have been recently introduced to cancer treatment research presenting various activities, such as antibacterial,
immunomodulatory, cell death, and anticancer. Less information exists regarding the therapeutic significance of these flavonoids
in cancer treatment, especially in overcoming multidrug resistance (MDR). Here, we tempted to investigate the potency of these
agents in reversing MDR by analyzing their effects as chemosensitizers on cell cytotoxicity, P-gp and ABCG2 protein expression
levels, and their function on two multidrug-resistant cell lines, P-gp-overexpressing human gastric adenocarcinoma cell line
(EPG85.257RDB) and ABCG2-overexpressing human epithelial breast cancer cell line (MCF7/MX).*e inhibitory concentration
of 10% (IC10) of bavachinin, tephrosin, and candidone in EPG85.257RDB cells was 1588.7± 202.2, 264.8± 86.15, and
1338.6± 114.11 nM, respectively. Moreover, these values in MCF7/MX cell were 2406.4± 257.63, 38.8± 4.28, and 27.9± 5.59 nM,
respectively. Expression levels of ABCG2 and P-gp were not significantly downregulated by these flavonoids. Maximum levels of
daunorubicin and mitoxantrone accumulations and minimum rates of drug efflux in both cell lines were detected 48 hrs
posttreatment with tephrosin and bavachinin, respectively. Chemosensitization to mitoxantrone and daunorubicin treatments
was, respectively, achieved in MCF7/MX and EPG85.257RDB cells in response to IC10 of bavachinin and tephrosin, in-
dependently. *ese effects did not follow time-dependent manner, and each flavonoid had its cell-dependent patterns. Overall,
bavachinin, tephrosin, and candidone showed potency to sensitize MDR cells to daunorubicin and mitoxantrone and could be
considered as attractive MDR modulators for cancer treatment. However, their action was time and cell specific.
1. Introduction
A major problem in cancer chemotherapy is drug resistance,
not only to single, but to multiple drugs, which significantly
compromises treatment outcomes. *is phenotype is known
as multidrug resistance (MDR), which is characterized by
reduced intracellular drug accumulation leading to treatment
failure. Variety of factors causes drug resistance; among them,
overexpression of ATP-binding cassette (ABC) transporters is
themost frequently occurring factor [1, 2]. So far, 49members
of human ABC transporter family have been discovered;
among them, P-glycoprotein (P-gp, also referred to ABCB1 or
MDR1) and ABCG2 (MXR or BCRP) which are the im-
portant members of ABC family attribute to MDR in cancer
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